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To the Editor,
In a recent interesting monocentre, prospective study 
published in the Turkish Journal of Medical Sciences, Bilgin 
et al. found a prevalence of Helicobacter pylori (H. pylori) 
antibodies (both IgM and IgG) significantly higher among 
systemic sclerosis (SSc) patients (73.3%) than in controls 
(46.6%) (P < 0.05) (1).   
In the latest two decades, several studies have reported 
potential links between chronic H. pylori infection and a 
variety of extragastric manifestations; these include ischemic 
heart disease, liver diseases, skin diseases, rheumatic diseases, 
blood disorders, and others (2).
Although the etiology of SSc remains uncertain, it has 
been reported that viral or bacterial infections can trigger 
autoimmune diseases. Some researchers have suggested that 
the production of specific autoantibodies in SSc patients is 
the result of an antigen-driven response caused by molecular 
mimicry (3) and the endothelial cells may be infected by 
bacteria that may be instrumental in inducing vasculitis, 
hence the importance of looking for infectious causal 
mechanisms. 
The findings of the study by Bilgin et al. (1) and the 
conflicting results in the literature (4,5) deserve attention. It 
is crucial to avoid selection biases. In particular, defining the 
control group is a key step in planning and conducting a study. 
The control group is used to compare the history of exposure 
in the cases with that in individuals who are free of the 
study disease. Individuals selected as controls should not 
only be free of the study disease, but should also be similar 
to the cases in regards to past potential for exposure. Stated 
somewhat differently, controls should be comparable to 
the cases in the sense that both groups would have been 
at equal risk of exposure if there were no disease-exposure 
association (6). H. pylori infection is associated with low 
socio-economic conditions and this should be taken into 
account when the control populations are selected (7). In 
assessing socio-economic status, its broad nature and the 
variety of elements that it includes should be recognised. 
Hence, such studies would require socially homogeneous 
populations to minimise confounding factors.
This information is not reported in the paper by Bilgin 
et al. (1); moreover, the authors reported a prevalence of H. 
pylori infection in the controls of only 46.6%, diagnosed by 
antibodies to H. pylori in serum, markers of exposure, and 
not necessarily of true infection, while in the literature (8) 
in Turkey H. pylori prevalence is very high, with a weighted 
overall prevalence of 82.5% tested with the urea breath 
test, able to diagnose the direct presence of the bacterium.
In conclusion, Bilgin et al. should report details about 
the control groups; this could enrich their findings.
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To The Editor;
We thank Dr Ribaldone for his interest in our article 
entitled “The prevalence of infectious agents in patients 
with systemic sclerosis” regarding the evaluation of the 
association between past and recent infections and the 
etiology of systemic sclerosis (1). We agree with his opinion 
that the control group should be similar to the cases in 
regards to past potential for exposure. In our study, the 
control group was similar to the study group in terms of 
age and sex. We conducted the study in the central parts 
of Turkey. However, we did not take into account socio-
economic status when both groups were determined. 
The prevalence of H. pylori infection differs among 
developing and developed countries. The prevalence of 
H. pylori infection is not more than 10% in developed 
countries, whereas it may reach up to 75%–80% in 
developing countries. In the studies carried out in different 
areas of Turkey, the rates of H. pylori positivity were found 
by Kesli et al. (2) to be 36.9%, by Us et al. (3) 53%, by 
Kaklıkaya et al. (4) 58.6%, and by Erzin et al. (5) 86%. In 
our study, the prevalence of H. pylori antibodies was 73.3% 
in SSc patients and 46.6% in the control group.
The infection prevalence alone should not be expected 
to provide adequate evidence for or against a pathological 
role in SSc. Thus, additional factors such as coinfections, 
and immunological and genetic host factors will have to be 
further identified and controlled to understand the role of 
infectious agents in SSc.
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